Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML1260

Sigma-Aldrich

HLM006474

≥98% (HPLC)

Sinônimo(s):

7-[(4-Ethoxy-3-methylphenyl)(2-pyridinylamino)methyl]-2-methyl-8-quinolinol

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

5 MG
R$ 741,00
25 MG
R$ 2.985,00

R$ 741,00


Check Cart for Availability

Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
5 MG
R$ 741,00
25 MG
R$ 2.985,00

About This Item

Fórmula empírica (Notação de Hill):
C25H25N3O2
Número CAS:
Peso molecular:
399.48
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77

R$ 741,00


Check Cart for Availability

Solicite uma grande encomenda

Nível de qualidade

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 5 mg/mL, clear (warmed)

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC1=CC(C(NC2=NC=CC=C2)C3=C(O)C(N=C(C)C=C4)=C4C=C3)=CC=C1OCC

InChI

1S/C25H25N3O2/c1-4-30-21-13-11-19(15-16(21)2)23(28-22-7-5-6-14-26-22)20-12-10-18-9-8-17(3)27-24(18)25(20)29/h5-15,23,29H,4H2,1-3H3,(H,26,28)

chave InChI

CYNZBLNMIJNBSF-UHFFFAOYSA-N

Aplicação

HLM006474 has been used as an E2 factor (E2F) inhibitor in human nasopharyngeal carcinoma hone-1 cells[1] and T. annulata-infected TBL20 cells.[2]

Ações bioquímicas/fisiológicas

HLM006474 activates p53 and induces DNA damage and apoptosis in mouse tumor models.[3]
HLM006474 is a pan-E2F transcription factor inhibitor.
HLM006474 is a pan-E2F transcription factor inhibitor. E2F s part of the CDK/Rb/E2F pathway. When phosphorylated by CDKs, the tumor suppressor retinoblastoma protein (Rb) is inactivated, releasing E2Fs and allowing cell cycle progression. HLM006474 inhibited DNA-binding of all E2F complexes and down-regulated expression of E2F4 protein. HLM006474 induced apoptosis of A375 melanoma cells and synergized with paclitaxel in lung cancer cell lines.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Keisuke Omori et al.
Oncogene, 42(33), 2485-2494 (2023-07-05)
Osteosarcoma (OS) is characterized by TP53 mutations in humans. In mice, loss of p53 triggers OS development, and osteoprogenitor-specific p53-deleted mice are widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms underlying the initiation or progression of
Florian Rouaud et al.
Cell death & disease, 9(5), 527-527 (2018-05-11)
Melanoma is one of the most lethal cancers when it reaches a metastatic stage. Despite advancements in targeted therapies (BRAF inhibitors) or immunotherapies (anti-CTLA-4 or anti-PD1), most patients with melanoma will need additional treatment. Thus, there is an urgent need
Yu-Yan Lan et al.
Biochemical and biophysical research communications, 503(3), 2160-2166 (2018-08-08)
Clinical studies suggest a positive association between malignant progression of nasopharyngeal carcinoma (NPC) and Rta, a transcription factor of Epstein-Barr virus (EBV). However, Rta induces cellular senescence in vitro. To provide an underlying mechanism integrating these clues, we adapted a concept
Kyle Tretina et al.
Scientific reports, 10(1), 3982-3982 (2020-03-07)
Intracellular pathogens have evolved intricate mechanisms to subvert host cell signaling pathways and ensure their own propagation. A lineage of the protozoan parasite genus Theileria infects bovine leukocytes and induces their uncontrolled proliferation causing a leukemia-like disease. Given the importance
Hanzhao Zhang et al.
Cellular oncology (Dordrecht) (2023-08-22)
Retinoblastoma, a childhood cancer, is most frequently caused by bi-allelic inactivation of RB1 gene. However, other oncogenic mutations such as MYCN amplification can induce retinoblastoma with proficient RB1. Previously, we established RB1-proficient MYCN-overexpressing retinoblastoma models both in human organoids and

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica